ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, announced that the company has received full ethical institutional approval from the Human Research Ethics Committee (HREC) and regulatory approval from the Therapeutic Goods Administration (TGA) to conduct a phase 1 trial of its lead programme IOS-1002 in Australia. The first patients are expected to be enrolled in Q1, 2023. Primary endpoints of the phase 1, first-in-human, open-label, non-randomized, multicenter, dose-escalation cohort expansion study will be the safety and tolerability of the compound, while secondary endpoints include efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of IOS-1002. In the trial, the compound will be administered at various dose levels to patients with advanced solid tumors either as monotherapy or in combination with a PD-1 monoclonal antibody. The trial is expected to enroll up to 140 patients. "Advancing our lead compound IOS-1002 into a first-in-human trial is a major milestone for our team and provides a potential new option for patients," said Sean R. Smith, CEO of ImmunOs Therapeutics. "Our goal is not only to determine the safety, tolerability and activity of IOS-1002, but also to assess its clinical potential as both monotherapy and in combination with anti-PD-1 therapy, as supported by preclinical data." IOS-1002 is a first-in-class, multi-functional agent based on a naturally occurring human leukocyte antigen (HLA) that targets multiple immune checkpoints to activate both innate and adaptive immune cells, thereby leading to profound anti-tumor activity. "In preclinical trials, we have demonstrated the ability of IOS-1002 to bind to three different immune checkpoint targets, LILRB1 (ILT2), LILRB2 (ILT4) and KIR3DL1, leading to significantly increased anti-tumor responses of human macrophages, T cells, and NK cells," said Prof. Dr. Christoph Renner, chief medical officer of ImmunOs Therapeutics. "We are excited about the opportunity to evaluate IOS-1002 in patients, as the compound addresses key challenges in cancer immunotherapy. We believe it has the potential to help patients with advanced solid tumors who have no further treatment options."
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!